Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies

European Journal of Health Economics

Volumn 5, Issue 3, 2004, Pages 263-269

  Vondeling, Hindrik ^a   Iversen, Peter Bindslev ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Denmark; Diabetes mellitus; Glitazones; Pharmacoeconomic evaluation; Reimbursement decision making

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; AUTHORITY; BUDGET; CHRONOLOGY; COST EFFECTIVENESS ANALYSIS; DENMARK; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; GOVERNMENT; HEALTH CARE COST; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; TREATMENT INDICATION;

COST-BENEFIT ANALYSIS; DECISION MAKING; DENMARK; DIABETES MELLITUS, TYPE 2; ECONOMICS, PHARMACEUTICAL; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH, REIMBURSEMENT; SAFETY; THIAZOLIDINEDIONES;

EID: 6044273872     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-004-0235-4     Document Type: Article

References (27)

1. Laegemiddelstyrelsen (2001) Notat. Erfaringer med sundhedsø konomiske analyser i ansøgninger om generelt tilskud til laegemidler - gennemgang af udvalgte emner. Laegemiddelstyrelsen, København (Danish Medicines Agency. Experience with health economics analyses as part of requests for general reimbursement of pharmaceuticals - discussion of selected issues.) Danish Medicines Agency, Copenhagen (in Danish). http://www. laegemiddelstyrelsen.dk/tilskud/overblik/notat.asp. Cited 15 Apr 2003
2. Sundhedsministeriet (1998) Bilag I. Retningslinier for udarbejdelse af økonomiske analyser af laegemidler. I: Udfordringer på laegemiddelområdet. Betaenkning afgivet af Sundhedsministeriets Medicinudvalg. Sundhedsministeriet, Betaenkning nr. 1357. (Ministry of Health, Appendix I. Guidelines for pharmacoeconomic evaluation. In: Challenges and issues with regard to pharmaceuticals. Report issued by the Committee on Pharmaceuticals of the Ministry of Health. Report 1357). Copenhagen, pp 176-177 (in Danish)
3. Pedersen KM (2003) Pricing and reimbursement of drugs in Denmark. EJHE 4: 60-65
4. Diabetesforeningen (1998) Sukkersyge - en sygdom i eksplosiv vaekst. Et indblik i sukkersygens sundhedsøkonomiske betydning med forslag til forbedringer. Rapport nr. 1. Udgivet af Diabetes-foreningen (Diabetes Society. Diabetes mellitus - a disease with an extremely rapid increase in incidence. A review of the health economics consequences of diabetes with suggestions for improvement. Report Number 1. Danish Diabetes Society) (in Danish)
5. de Sonnaville JJJ, Heine RJ (1997) Non-insulin dependent diabetes mellitus: presentation and treatment. Medicine 25: 23-26
6. Barman Balfour JA, Plosker GL (1999) Rosiglitazone. Drugs 57: 921-930
7. FDA Talk Paper (2000) FDA's report on new health care products approved in 1999. FDA. URL: http://www.fda.gov/bbs/topics/ANSWERS/ANS0098.html. Cited 31 May 2002
8. FDA Talk Paper (1999) FDA Approves Rosiglitazone to treat Type II diabetes. FDA, US; May 26, 1999. http://www.fda.gov/bbs/topics/ANSWERS/ANS00957. html. Cited 31 May 2002
9. Gale EA (2001) Lessons from glitazones: a story of drug development. The Lancet 357:1870-1875
10. The European Agency for the Evaluation of Medicinal Products (EMEA). European Public Assessment Report (EPAR). CPMP/1043/00. Avandia. http://www.emea.eu.int/humandocs/PDFs/EPAR/Actos/201400en1.pdf. Cited 23 Sept 2003
11. The European Agency for the Evaluation of Medicinal Products (EMEA), European Public Assessment Report (EPAR). CPMP/2014/00. Actos. http://www.emea.eu.int/humandocs/PDFs/EPAR/Actos/201400en1.pdf. Cited 23 Sept 2003
12. Laegemiddelstyrelsen (2000) Documents and correspondence on reimbursement of rosiglitazone. File nr. 5311-199. Laegemiddelstyrelsen (Danish Medicines Agency), Copenhagen, Denmark (in Danish)
13. Laegemiddelstyrelsen (2000) Documents and correspondence on reimbursement of pioglitazone. File nr. 5311-209. Laegemiddelstyrelsen (Danish Medicines Agency), Copenhagen, Denmark (in Danish)
14. Institute for Rational Pharmacotherapy (2000) Rosiglitazone. http://www.irf.dk/dk/praeparatnyt/arkiv/avandia_rosiglitazone_02.htm. Cited 03 Sept 2001, revisited 29 May 2003. Avandia (rosiglitazone). Institute for Rational Pharmacotherapy, Copenhagen, Denmark (in Danish)
15. Institute for Rational Pharmacotherapy (2000) Pioglitazone. http://www.irf.dk/dk/praeparatnyt/arkiv/actos_pioglitazone_02.htm. Cited 03 Sept 2001, revisited 29 May 2003. Actos (pioglitazone). Institute for Rational Pharmacotherapy, Copenhagen, Denmark (in Danish)
16. Beck-Nielsen H, Henriksen JE, Hermansen K, Madsen LD, de Fine Olivarius N, Mandrup-Poulsen TR, Pedersen OB, Richelsen B, Schmitz OE (2000) Type 2 diabetes og det metaboliske syndrom - diagnostik og behandling. Dansk Selskab for Intern Medicin, Dansk Endokrinologisk Selskab, Dansk Selskab for Almen Medicin, Rapport Nr 6, 2000 (Type 2 diabetes and the metabolic syndrome - diagnosis and treatment. Danish Society for Internal Medicine, Danish Endocrinological Society, Danish Society for General Practitioners) (in Danish). Available at: http://www.dadlnet.dk/klaringsrapporter/2000-06.htm#1
17. Statens Institut for Medicinsk Teknologivurdering (2001) Etablering af et dansk system til tidlig varsling af nye teknologier. Rapport fra et pilotprojekt. Statens Institut for Medicinsk Teknologivurdering, Copenhagen, Denmark, 2001 (Danish Institute for Health Technology Assessment. Establishment of a Danish early warning system for new technologies. Report of a pilot project. Danish Institute for Health Technology Assessment, Copenhagen, Denmark (in Danish)
18. Krentz AJ, Bailey CJ, Melander A (2000) Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials. BMJ 321: 252-253
19. Netdoktor, Nyhederne D (2002) (Netdoktor news, daily service, in Danish). http://www.netdoktor.dk. Cited 21 Feb 2002
20. Laegemiddelstyrelsen (2000) Overblik over medicintilskud. Kriterier for enkelttilskud til visse typer af laegemidler (Danish Medicines Agency. Overview on reimbursement of pharmaceuticals. Criteria for individual reimbursement of selected pharmaceuticals (in Danish). http://www.laegemiddelstyrelsen.dk/ tilskud/overblik/ktiterier.asp. Cited 15 Oct 2001, revisited 29 May 2003
21. Kampman JP (2001) Glitazoner. Rational Farmakoterapi 10: 3 (in Danish)
22. Boucher M, McAuley L, Brown A, Keely E, Skidmore B (2003) Technology Overview No. 9. Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with other anti-diabetic agents. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa, Canada
23. Madsblad S (2001) Behandling af type 2 diabetes mellitus (Treatment of type 2 diabetes): Rationel Pharmacotherapy 9: 1-4 (in Danish)
24. Henriksson F (2002) Applications of economic models in health care. The introduction of pioglitazone in Sweden. PharmacoEconomics 20[Suppl 1]: 43-53
25. Jónsson B (ed) (2002) Use of economic models in formulary decisions: case studies of pioglitazone in international settings. PharmacoEconomics 20[Suppl 1]: 1-53
26. The European Agency for the Evaluation of Medicinal Products (EMEA) (1999) Note for guidance on procedure for competent authorities on the undertaking of pharmacovigilance activities. EMEA. http:www.emea.eu.int/pdfs/ human/phvwp/017595en.pdf, sections 3.2.3 and 3.3.3. Cited 20 Jan 2004
27. Stoykova S, Drummond M, Barbieri M, Kleijnen J (2003) The lag between effectiveness and cost-effectiveness evidence of new drugs. EJHE 4: 313-